Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024372755> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W2024372755 abstract "The Cardiovascular and Renal Advisory Panel of the FDA met January 27-28, 1998, to discuss (1) evaluation and use of intravenous inotropic agents in patients with heart failure; (2) liver function test abnormalities with a new AT1 receptor blocker, tasosartan; and (3) the use of the platelet IIb/IIIa receptor blocker eptifibatide in syndromes of acute cardiac ischemia.Intravenous drugs for the treatment of heart failure historically have been approved after demonstration of acute dose-dependent hemodynamic effects in patients with heart failure. Recently, however, there appears to have been a marked increase in the intermittent or continuous use of intravenous inotropic agents for longer periods than originally anticipated, often without monitoring of cardiac rhythm. This practice has become prevalent despite recent trials with oral inotropic agents that have shown adverse effects on mortality and morbidity during long-term treatment and preclinical data presented to the committee that raised the possibility that intermittent exposure to intravenously administered positive inotropic agents may accelerate myocardial cell death. The committee therefore voted unanimously that short-term use of intravenous inotropic agents for decompensated heart failure should be approved if an improvement in symptoms, renal function, and/or hemodynamics (including patients after bypass surgery) can be shown. However, for prolonged intermittent or continuous intravenous use, an improvement in survival and symptoms should be demonstrated in a placebo-controlled trial. The committee unanimously recommended that labeling of intravenous positive inotropic agents be revised to reflect the following: (1) that these drugs are indicated for patients who are hospitalized with acutely decompensated heart failure, (2) that there is no experience in controlled trials with continuous infusions for periods >24 to 48 hours, (3) that there is no evidence that these drugs are effective or …" @default.
- W2024372755 created "2016-06-24" @default.
- W2024372755 creator A5025536559 @default.
- W2024372755 creator A5058141203 @default.
- W2024372755 date "1998-06-16" @default.
- W2024372755 modified "2023-09-26" @default.
- W2024372755 title "FDA Panel Report: January 1998" @default.
- W2024372755 cites W2281862598 @default.
- W2024372755 doi "https://doi.org/10.1161/01.cir.97.23.2295" @default.
- W2024372755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9639370" @default.
- W2024372755 hasPublicationYear "1998" @default.
- W2024372755 type Work @default.
- W2024372755 sameAs 2024372755 @default.
- W2024372755 citedByCount "9" @default.
- W2024372755 crossrefType "journal-article" @default.
- W2024372755 hasAuthorship W2024372755A5025536559 @default.
- W2024372755 hasAuthorship W2024372755A5058141203 @default.
- W2024372755 hasBestOaLocation W20243727551 @default.
- W2024372755 hasConcept C126322002 @default.
- W2024372755 hasConcept C155710745 @default.
- W2024372755 hasConcept C164705383 @default.
- W2024372755 hasConcept C177713679 @default.
- W2024372755 hasConcept C197934379 @default.
- W2024372755 hasConcept C2775915353 @default.
- W2024372755 hasConcept C2777386981 @default.
- W2024372755 hasConcept C2778198053 @default.
- W2024372755 hasConcept C2779295919 @default.
- W2024372755 hasConcept C42219234 @default.
- W2024372755 hasConcept C71924100 @default.
- W2024372755 hasConceptScore W2024372755C126322002 @default.
- W2024372755 hasConceptScore W2024372755C155710745 @default.
- W2024372755 hasConceptScore W2024372755C164705383 @default.
- W2024372755 hasConceptScore W2024372755C177713679 @default.
- W2024372755 hasConceptScore W2024372755C197934379 @default.
- W2024372755 hasConceptScore W2024372755C2775915353 @default.
- W2024372755 hasConceptScore W2024372755C2777386981 @default.
- W2024372755 hasConceptScore W2024372755C2778198053 @default.
- W2024372755 hasConceptScore W2024372755C2779295919 @default.
- W2024372755 hasConceptScore W2024372755C42219234 @default.
- W2024372755 hasConceptScore W2024372755C71924100 @default.
- W2024372755 hasLocation W20243727551 @default.
- W2024372755 hasLocation W20243727552 @default.
- W2024372755 hasOpenAccess W2024372755 @default.
- W2024372755 hasPrimaryLocation W20243727551 @default.
- W2024372755 hasRelatedWork W1489783725 @default.
- W2024372755 hasRelatedWork W1506200166 @default.
- W2024372755 hasRelatedWork W2039318446 @default.
- W2024372755 hasRelatedWork W2080531066 @default.
- W2024372755 hasRelatedWork W2148612803 @default.
- W2024372755 hasRelatedWork W2373994074 @default.
- W2024372755 hasRelatedWork W2748952813 @default.
- W2024372755 hasRelatedWork W2780146991 @default.
- W2024372755 hasRelatedWork W2899084033 @default.
- W2024372755 hasRelatedWork W3012411836 @default.
- W2024372755 isParatext "false" @default.
- W2024372755 isRetracted "false" @default.
- W2024372755 magId "2024372755" @default.
- W2024372755 workType "article" @default.